Nanostructured Lipid Carrier Development and Optimization for Schizophrenia: A Psychological Study

Abstract

The experimental work and design on the creation and enhanced of a quetiapine fumarate nanostructured lipid transport system for oral drug delivery of used for disease treatment of Schizophrenia. Because quetiapine fumarate is a substrate for Para-glycoprotein inhibitors organize on the surface of the gut and endothelial cells of the BBB. An inhibitor of curcumin is used as drug aid substance entrance to these cells. It was also planned to increase the drug's bioavailability, as it belongs to biopharmaceutical categorization system class II and has a low oral bioavailability of 9%, with a low dose so that the drug's negative effects could be avoided. Hot homogenization method was used to design nanostructured lipid transport systems from cholesterol and oleic acid prepared from different types of lipids one is solid lipid and liquid lipid, respectively. Various types of Surfactant are used in the formulation of nano structured lipid transport system that is vitamin E, tocopherol and  polyethylene glycol succinate, which has frequent properties. The primary aim was to enhanced lipid concentration through various experimental design. The respondent were simultaneously charcterized using Deringer's desirability function, which yielded a desirability value of D 0.893, indicating a high degree of global optimisation. To evaluate quetiapine fumarate and curcumin in formulations, a simultaneous approach using RP-HPLC was devised. The configuration of  nanostructured lipid transport  were characterised for several physiochemical properties, as well as the influence  of cholesterol and oleic acid on particle size and transparency. Ex vivo permeability tests were performed to examine the effect of curcumin when coupled with quetiapine fumarate.